All News

A recent spate of false positive results using OraSure’s test has officials and company representatives scrambling to figure out what is causing these anomalies and how to stop them from impacting testing rates.

Agency hopes to inform healthcare providers and patients about comparisons of treatments for gastroesophagealreflux disease.

Medicus International has been successfully developing global communications for 30 years.

Many companies start up “eClinical” projects. But what is eClinical – and how does it support the R&D strategy?

The embattled pharma company needs to walk a tightrope between reassuring employees and pleasing investors. Can it succeed? Analysts and personnel experts share their insights.

The electronic revolution in clinical trials is still a work in progress, but researchers say it's time to bring EDC to the preclinical world.

A new understanding about how one class of bacteria protects itself from the environment could dramatically cut tuberculosis treatment time.

Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year-if you like roller coasters.

Some people are infected by HIV strains that are already resistant to FDA-approved drugs because they were transmitted by someone who developed resistance while receiving antiretroviral therapy. As a result, these patients often fail therapy.

December 2005 CE.

Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and-at last-innovative mechanisms for troublesome targets.

PharmExec's 2005 Pharma Knowledge Quiz

The biggest threat to the success of polio eradication is Nigeria, where the immunization program was suspended on religious grounds in some parts of the country in 2003 and 2004.

Find out how you did on our December 2005 quiz.

Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again-more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives-a figure the World Health Organization (WHO) quickly retracted.

Pargluva was a bad bet from early on. Analysts say so. Can BMS still save face?

Log on to CrazyMeds.org. Find out what patients say about your drugs, and what they think doctors and pharma don’t tell them.

Animal-rights activists call for attacks on testing facilities. Congress calls activists terrorists. Industry leaders propose a response.

A look at what the editors of Pharmaceutical Representative have planned for 2006.

Legal experts analyze the differences between the first two Vioxx trials and what allowed Merck to be successful this time around. They also offer insight about what to expect going forward.

The Critical Path is alive and well, as demonstrated by an agreement between FDA and Massachusetts-based BG Medicine to identify molecules associated with liver toxicity in animal trials.

The success of a 1999 program to vaccinate children in high-risk areas against Hepatitis A prompted the Advisory Committee on Immunization Practices to recommend universal use. But the vaccine may face minor hurdles from insurance companies and states.

PharmRep06Rates

PharmRep06Cal

PharmRep06CalRates

November 2005 CE.

PhRMA Guiding Principle number 10 calls for the banishment of reminder ads. While there are many reasons why drug ads truly advance the public health, there are no good arguments for why reminder ads advance public health in any way.

Leo H. Sternbach's death feels like the end of an era, a time when the new drugs came easily and it was possible to have a huge impact on patients, then turn around and do it again.

A new meta-analysis confirms the risk of atypical antipsychotics noted by FDA earlier this year. But the reasons for this increased incidence of death remain unclear.

Merck and GSK’s cervical cancer vaccines promise great benefits to women-but there are several key hurdles to clear before the drugs can become the blockbusters the companies are predicting. Analysts debate how long it will take it will take to overcome these obstacles.